MabThera

News

Sandoz has gained European approval for its biosimilar version of Roche's blockbuster MabThera/Rituxan (rituximab) to be called Rixathon.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.